International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands : beyond CB1 and CB2. / Pertwee, R G; Howlett, A C; Abood, M E; Alexander, S P H; Di Marzo, V; Elphick, M R; Greasley, P J; Hansen, Harald S.; Kunos, G; Mackie, K; Mechoulam, R; Ross, R A.

In: Pharmacological Reviews, Vol. 62, No. 4, 01.12.2010, p. 588-631.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Pertwee, RG, Howlett, AC, Abood, ME, Alexander, SPH, Di Marzo, V, Elphick, MR, Greasley, PJ, Hansen, HS, Kunos, G, Mackie, K, Mechoulam, R & Ross, RA 2010, 'International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2', Pharmacological Reviews, vol. 62, no. 4, pp. 588-631. https://doi.org/10.1124/pr.110.003004

APA

Pertwee, R. G., Howlett, A. C., Abood, M. E., Alexander, S. P. H., Di Marzo, V., Elphick, M. R., Greasley, P. J., Hansen, H. S., Kunos, G., Mackie, K., Mechoulam, R., & Ross, R. A. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacological Reviews, 62(4), 588-631. https://doi.org/10.1124/pr.110.003004

Vancouver

Pertwee RG, Howlett AC, Abood ME, Alexander SPH, Di Marzo V, Elphick MR et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacological Reviews. 2010 Dec 1;62(4):588-631. https://doi.org/10.1124/pr.110.003004

Author

Pertwee, R G ; Howlett, A C ; Abood, M E ; Alexander, S P H ; Di Marzo, V ; Elphick, M R ; Greasley, P J ; Hansen, Harald S. ; Kunos, G ; Mackie, K ; Mechoulam, R ; Ross, R A. / International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands : beyond CB1 and CB2. In: Pharmacological Reviews. 2010 ; Vol. 62, No. 4. pp. 588-631.

Bibtex

@article{63a651f5e3c3454f95147d57f1ecbbd7,
title = "International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2",
abstract = "There are at least two types of cannabinoid receptors (CB(1) and CB(2)). Ligands activating these G protein-coupled receptors (GPCRs) include the phytocannabinoid ¿(9)-tetrahydrocannabinol, numerous synthetic compounds, and endogenous compounds known as endocannabinoids. Cannabinoid receptor antagonists have also been developed. Some of these ligands activate or block one type of cannabinoid receptor more potently than the other type. This review summarizes current data indicating the extent to which cannabinoid receptor ligands undergo orthosteric or allosteric interactions with non-CB(1), non-CB(2) established GPCRs, deorphanized receptors such as GPR55, ligand-gated ion channels, transient receptor potential (TRP) channels, and other ion channels or peroxisome proliferator-activated nuclear receptors. From these data, it is clear that some ligands that interact similarly with CB(1) and/or CB(2) receptors are likely to display significantly different pharmacological profiles. The review also lists some criteria that any novel {"}CB(3){"} cannabinoid receptor or channel should fulfil and concludes that these criteria are not currently met by any non-CB(1), non-CB(2) pharmacological receptor or channel. However, it does identify certain pharmacological targets that should be investigated further as potential CB(3) receptors or channels. These include TRP vanilloid 1, which possibly functions as an ionotropic cannabinoid receptor under physiological and/or pathological conditions, and some deorphanized GPCRs. Also discussed are 1) the ability of CB(1) receptors to form heteromeric complexes with certain other GPCRs, 2) phylogenetic relationships that exist between CB(1)/CB(2) receptors and other GPCRs, 3) evidence for the existence of several as-yet-uncharacterized non-CB(1), non-CB(2) cannabinoid receptors; and 4) current cannabinoid receptor nomenclature.",
keywords = "Cannabinoids, Endocannabinoids, Humans, Ligands, Phylogeny, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2, Receptors, Cannabinoid, Terminology as Topic",
author = "Pertwee, {R G} and Howlett, {A C} and Abood, {M E} and Alexander, {S P H} and {Di Marzo}, V and Elphick, {M R} and Greasley, {P J} and Hansen, {Harald S.} and G Kunos and K Mackie and R Mechoulam and Ross, {R A}",
year = "2010",
month = dec,
day = "1",
doi = "10.1124/pr.110.003004",
language = "English",
volume = "62",
pages = "588--631",
journal = "Pharmacological Reviews",
issn = "0031-6997",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "4",

}

RIS

TY - JOUR

T1 - International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands

T2 - beyond CB1 and CB2

AU - Pertwee, R G

AU - Howlett, A C

AU - Abood, M E

AU - Alexander, S P H

AU - Di Marzo, V

AU - Elphick, M R

AU - Greasley, P J

AU - Hansen, Harald S.

AU - Kunos, G

AU - Mackie, K

AU - Mechoulam, R

AU - Ross, R A

PY - 2010/12/1

Y1 - 2010/12/1

N2 - There are at least two types of cannabinoid receptors (CB(1) and CB(2)). Ligands activating these G protein-coupled receptors (GPCRs) include the phytocannabinoid ¿(9)-tetrahydrocannabinol, numerous synthetic compounds, and endogenous compounds known as endocannabinoids. Cannabinoid receptor antagonists have also been developed. Some of these ligands activate or block one type of cannabinoid receptor more potently than the other type. This review summarizes current data indicating the extent to which cannabinoid receptor ligands undergo orthosteric or allosteric interactions with non-CB(1), non-CB(2) established GPCRs, deorphanized receptors such as GPR55, ligand-gated ion channels, transient receptor potential (TRP) channels, and other ion channels or peroxisome proliferator-activated nuclear receptors. From these data, it is clear that some ligands that interact similarly with CB(1) and/or CB(2) receptors are likely to display significantly different pharmacological profiles. The review also lists some criteria that any novel "CB(3)" cannabinoid receptor or channel should fulfil and concludes that these criteria are not currently met by any non-CB(1), non-CB(2) pharmacological receptor or channel. However, it does identify certain pharmacological targets that should be investigated further as potential CB(3) receptors or channels. These include TRP vanilloid 1, which possibly functions as an ionotropic cannabinoid receptor under physiological and/or pathological conditions, and some deorphanized GPCRs. Also discussed are 1) the ability of CB(1) receptors to form heteromeric complexes with certain other GPCRs, 2) phylogenetic relationships that exist between CB(1)/CB(2) receptors and other GPCRs, 3) evidence for the existence of several as-yet-uncharacterized non-CB(1), non-CB(2) cannabinoid receptors; and 4) current cannabinoid receptor nomenclature.

AB - There are at least two types of cannabinoid receptors (CB(1) and CB(2)). Ligands activating these G protein-coupled receptors (GPCRs) include the phytocannabinoid ¿(9)-tetrahydrocannabinol, numerous synthetic compounds, and endogenous compounds known as endocannabinoids. Cannabinoid receptor antagonists have also been developed. Some of these ligands activate or block one type of cannabinoid receptor more potently than the other type. This review summarizes current data indicating the extent to which cannabinoid receptor ligands undergo orthosteric or allosteric interactions with non-CB(1), non-CB(2) established GPCRs, deorphanized receptors such as GPR55, ligand-gated ion channels, transient receptor potential (TRP) channels, and other ion channels or peroxisome proliferator-activated nuclear receptors. From these data, it is clear that some ligands that interact similarly with CB(1) and/or CB(2) receptors are likely to display significantly different pharmacological profiles. The review also lists some criteria that any novel "CB(3)" cannabinoid receptor or channel should fulfil and concludes that these criteria are not currently met by any non-CB(1), non-CB(2) pharmacological receptor or channel. However, it does identify certain pharmacological targets that should be investigated further as potential CB(3) receptors or channels. These include TRP vanilloid 1, which possibly functions as an ionotropic cannabinoid receptor under physiological and/or pathological conditions, and some deorphanized GPCRs. Also discussed are 1) the ability of CB(1) receptors to form heteromeric complexes with certain other GPCRs, 2) phylogenetic relationships that exist between CB(1)/CB(2) receptors and other GPCRs, 3) evidence for the existence of several as-yet-uncharacterized non-CB(1), non-CB(2) cannabinoid receptors; and 4) current cannabinoid receptor nomenclature.

KW - Cannabinoids

KW - Endocannabinoids

KW - Humans

KW - Ligands

KW - Phylogeny

KW - Receptor, Cannabinoid, CB1

KW - Receptor, Cannabinoid, CB2

KW - Receptors, Cannabinoid

KW - Terminology as Topic

U2 - 10.1124/pr.110.003004

DO - 10.1124/pr.110.003004

M3 - Journal article

C2 - 21079038

VL - 62

SP - 588

EP - 631

JO - Pharmacological Reviews

JF - Pharmacological Reviews

SN - 0031-6997

IS - 4

ER -

ID: 33221398